U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT07584850) titled 'Evaluation of GI001 for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma' on April 19.
Brief Summary: The goal of this clinical trial is to evaluate the safety, tolerability, and preliminary efficacy in adult patients with relapsed or refractory (r/r) CD19-positive B-cell Non-Hodgkin Lymphoma (B-NHL) or B-cell Leukemia. The main questions it aims to answer are:
* What are the safety and tolerability profiles of GI001, specifically regarding the incidence of Dose-Limiting Toxicities (DLTs) and the determination of the Maximum Tolerated Dose (MTD)?
* What is the preliminary efficacy of GI001, measured by Objective Response Rate (OR...